TP53 and non-small cell lung carcinoma: Notably, almost two-thirds of individuals with NSCLC contain oncogenic driver mutations, and around half of them have therapeutically targeted lesions (5, 6).Common genetic changes include mutations in TP53, EGFR and KRAS, as well as fusions of EML4-ALK and ROS1 (7).